IDEXX Laboratories Inc (IDXX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at IDEXX Laboratories Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 559.10 $ — 14% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 26.5% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 13
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 14.66 | 14.48 – 14.82 | 4,708 | 12.1% | 12 |
| 12/31/2027 | 16.52 | 16.20 – 16.97 | 5,115 | 12.6% | 14 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 3.95 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 2.60 | 12.30 | 954 | 5.80 | 22.70 | 262 | 223 |
| 2025: Q1 | 2.96 | 5.60 | 998 | 3.60 | 24.30 | 238 | 208 |
| 2025: Q2 | 3.63 | 48.90 | 1,110 | 10.60 | 26.50 | 186 | 152 |
| 2025: Q3 | 3.40 | 21.40 | 1,105 | 13.30 | 24.80 | 402 | 371 |
| 2025: Q4 | 3.08 | 18.20 | 1,091 | 14.30 | 22.80 | 352 | 323 |
| 2026: Q1 | 3.45 | 16.50 | 1,141 | 14.30 | 24.40 | 266 | 234 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,775 | 350 | 222 | 2.44 | 335 | -108 | 1,531 |
| 2017 | 1,969 | 413 | 263 | 2.94 | 373 | -54 | 1,713 |
| 2018 | 2,213 | 491 | 377 | 4.26 | 400 | -10 | 1,537 |
| 2019 | 2,407 | 553 | 428 | 4.89 | 459 | 177 | 1,832 |
| 2020 | 2,707 | 695 | 582 | 6.71 | 648 | 632 | 2,295 |
| 2021 | 3,215 | 932 | 745 | 8.60 | 756 | 690 | 2,437 |
| 2022 | 3,367 | 899 | 679 | 8.03 | 543 | 609 | 2,747 |
| 2023 | 3,661 | 1,097 | 845 | 10.06 | 907 | 1,485 | 3,260 |
| 2024 | 3,898 | 1,128 | 888 | 10.69 | 929 | 1,595 | 3,293 |
| 2025 | 4,304 | 1,360 | 1,059 | 13.13 | 1,178 | 1,605 | 3,351 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
IDEXX Laboratories, Inc. entwickelt, fertigt und vertreibt Produkte für die Bereiche Kleintiermedizin, Nutztier- und Geflügelhaltung, Milchwirtschaft und Wassertestung in den USA und international.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 11,000 |
| Headquarters | Westbrook, ME |
| Address | One IDEXX Drive, 04092 Westbrook, United States |
| Phone | 207 556 0300 |
| Website | idexx.com |
| IPO Date | 21. Jun 1991 |
| ISIN | US45168D1046 |
| Stock Split | 2:1 on 06/16/2015 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jonathan J. Mazelsky | Executive Chairman | 1961 |
| Andrew Emerson | Executive VP, CFO & Treasurer | 1983 |
| Michael J. Lane | Executive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | 1968 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.